Our data reveals the co-occurrence of KRAS, NRAS, and BRAF mutations (Table 2 and Table 3) in CRC, which could explain why only a reduced number of patients (10–20%) respond to single-agent treatments based on anti-EGFR antibodies [36]. This evidence concerns the gene BRAF and colorectal carcinoma.